Marinomed Biotech AG Ceases Operations Following Insolvency Ruling

Marinomed Biotech AG has faced significant financial challenges following the failure to receive expected payments from Unither Pharmaceuticals. On July 22, the company filed for court-supervised restructuring. The situation reached a critical point as insolvency administrator Dr. Ulla Reisch submitted a proposal to terminate business activities. The insolvency court accepted this motion, effectively mandating the cessation of operations for Marinomed. Subsequently, Dr. Reisch is set to initiate a process to liquidate the company's assets. This development led First Berlin Equity Research to discontinue their coverage of Marinomed Biotech AG.